Next Article in Journal
NSAIDs and Acute Pancreatitis: A Systematic Review
Next Article in Special Issue
Differential Proteomics Identification of HSP90 as Potential Serum Biomarker in Hepatocellular Carcinoma by Two-dimensional Electrophoresis and Mass Spectrometry
Previous Article in Journal
Inhaled Corticosteroids
Previous Article in Special Issue
Real Time Imaging of Biomarkers in the Parkinson's Brain Using Mini-Implantable Biosensors. II. Pharmaceutical Therapy with Bromocriptine
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(3), 541-557; doi:10.3390/ph3030541

Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure

Department of Chemistry & Biochemistry, University of Delaware, Newark, DE, 19716, USA
Author to whom correspondence should be addressed.
Received: 9 January 2010 / Revised: 7 February 2010 / Accepted: 5 March 2010 / Published: 8 March 2010
(This article belongs to the Special Issue Biomarkers)
View Full-Text   |   Download PDF [2256 KB, uploaded 8 March 2010]   |  


Plasma platelet-activating factor acetylhydrolase (PAF-AH), also called lipoprotein-associated phospholipase A2 (Lp-PLA2), is a group VIIA PLA2 enzyme that catalyzes the hydrolysis of PAF and certain oxidized phospholipids. Although the role of PAF-AH as a pro- or anti-atherosclerotic enzyme is highly debated, several studies have shown it to be an independent marker of cardiovascular diseases. In humans the majority of plasma PAF-AH is bound to LDL and a smaller portion to HDL; the majority of the enzyme being associated with small dense LDL and VHDL-1 subclasses. Several studies suggest that the anti- or pro-atherosclerotic tendency of PAF-AH might be dependent on the type of lipoprotein it is associated with. Amino acid residues in PAF-AH necessary for binding to LDL and HDL have been identified. However our understanding of the interaction of PAF-AH with LDL and HDL is still incomplete. In this review we present an overview of what is already known about the interaction of PAF-AH with lipoprotein particles, and we pose questions that are yet to be answered. The recently solved crystal structure of PAF-AH, along with functional work done by others is used as a guide to develop a model of interaction of PAF-AH with lipoprotein particles. View Full-Text
Keywords: PAF-AH; Lp-PLA2; group VIIA PLA2; lipoprotein; i-face PAF-AH; Lp-PLA2; group VIIA PLA2; lipoprotein; i-face

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Srinivasan, P.; Bahnson, B.J. Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure. Pharmaceuticals 2010, 3, 541-557.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top